Novel Alzheimer’s Therapies Given to Less than 20 Percent of Applicants in Japan

Novel Alzheimer's therapies have been given to 19 pct of outpatients who applied for the medications, according to a recent survey at a Tokyo hospital. The lecanemab and donanemab therapies for early-stage Alzheimer's patients are now clinically available under Japan's national health insurance scheme, which curbs a sharp rise in out-of-pocket medical expenses. Despite the relatively low-cost availability, however, the drugs have eventually been administered to only 87 out of 456 applicants, the survey by a study group at the Tokyo Metropolitan Institute for Geriatrics and Gerontology showed. Episode notes: ‘Novel Alzheimer’s Therapies Given to Less than 20 Percent of Applicants’: https://barrierfreejapan.com/2026/04/08/novel-alzheimers-therapies-given-to-less-than-20-percent-of-applicants/